Archives — September 2017 back to current month (5)
H.C. Wainwright & Co. reported the results of animal studies conducted using therapeutics created by this cancer and chronic infectious disease vaccine developer.
André Uddin, an analyst with Mackie Research, explained the rationale for adding this neurodegenerative disease biotech company to his firm's coverage universe.
Gout, Kidney Stones, Liver Disease & Cannabinoids (09/15/2017)
Danny Deadlock, founder of Microcap.com, profiles a company that is working on a novel drug delivery technology with a focus on cannabinoids for the potential to treat various major diseases.
Biopharma Gets Green Light for Hypertension Study (09/13/2017)
Jason McCarthy, an analyst at Maxim Group, discussed this France-based biotech firm's near-term clinical trial and catalysts.
The first approval of a cell therapy for treatment of pediatric blood cancer prompted H. C. Wainwright to increase its price target for a UK-based biotech manufacturing one of the therapy's components.
|"PMN is looking to outlicense PMN310 after the Phase 1 study."|
|"DRRX intends to start a NASH trial as soon as H1/19."|
|"VIVs recent distribution deals illustrate demand for its technology."|